<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03286218</url>
  </required_header>
  <id_info>
    <org_study_id>16853</org_study_id>
    <secondary_id>H8H-MC-LAHB</secondary_id>
    <nct_id>NCT03286218</nct_id>
  </id_info>
  <brief_title>A Study of the Abuse Potential of Lasmiditan in Participants Who Are Recreational Drug Users</brief_title>
  <official_title>A Randomized, Subject- and Investigator-Blind, Placebo and Active-Controlled Study to Assess the Abuse Potential of Lasmiditan</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the abuse potential of study drug lasmiditan.

      Lasmiditan will be compared to a marketed benzodiazepine, alprazolam (positive control), as
      well as to placebo (dummy substance that looks like lasmiditan or alprazolam without any
      active drug) to determine the potential for drug abuse. The dosages will be in tablet form
      and will be taken orally (by mouth).

      This study will last about 55 days, including screening. Screening will occur within 28 days
      prior to qualification phase.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 15, 2017</start_date>
  <completion_date type="Actual">November 20, 2017</completion_date>
  <primary_completion_date type="Actual">November 20, 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from Baseline in Maximal Effect Score (Emax) of Bipolar Drug Liking Visual Analog Scale (VAS) Scores</measure>
    <time_frame>Baseline through 24 hours post dose in each treatment period</time_frame>
    <description>Drug Liking VAS</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PK): Maximum Observed Drug Concentration (Cmax) of Lasmiditan</measure>
    <time_frame>Baseline through 24 hours post dose in each treatment period</time_frame>
    <description>PK: Cmax of Lasmiditan</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PK): Area Under the Curve (AUC) of Lasmiditan</measure>
    <time_frame>Baseline through 24 hours post dose in each treatment period</time_frame>
    <description>PK: AUC of Lasmiditan</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Scores on Drug Effects Visual Analog Scale (VAS) Measures</measure>
    <time_frame>Baseline through 24 hours post dose in each treatment period</time_frame>
    <description>Drug Effects VAS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Scores on Drug Similarity Visual Analog Scale (VAS) Measures</measure>
    <time_frame>Baseline through 24 hours post dose in each treatment period</time_frame>
    <description>Drug Similarity VAS</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">130</enrollment>
  <condition>Recreational Drug Use</condition>
  <condition>Prescription Drug Abuse (Not Dependent)</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo administered orally in one of five treatment periods</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Alprazolam</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Alprazolam administered orally in one of five treatment periods</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lasmiditan - Low Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Low dose of lasmiditan administered orally in one of five treatment periods</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lasmiditan - Medium Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Medium dose of lasmiditan administered orally in one of five treatment periods</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lasmiditan - High Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>High dose of lasmiditan administered orally in one of five treatment periods</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lasmiditan</intervention_name>
    <description>Administered orally</description>
    <arm_group_label>Lasmiditan - Low Dose</arm_group_label>
    <arm_group_label>Lasmiditan - Medium Dose</arm_group_label>
    <arm_group_label>Lasmiditan - High Dose</arm_group_label>
    <other_name>LY573144</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Alprazolam</intervention_name>
    <description>Administered orally</description>
    <arm_group_label>Alprazolam</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Administered orally</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Are overtly healthy males or females, as determined by medical history and physical
             examination.

          -  Have a body mass index (BMI) of 18 to 32 kilograms per meter squared (kg/mÂ²)
             inclusive, at the time of screening.

          -  Must be recreational drug user and agree not to consume any recreational drugs during
             the study.

        Exclusion Criteria:

          -  Have known allergies to lasmiditan, alprazolam, related compounds, or any components
             of the formulation, or a history of significant atopy.

          -  Are currently seeking or participating in treatment for addiction or substance-related
             disorders, or have recovered from substance abuse disorder.

          -  Are currently taking excluded prescription or over-the-counter (OTC) medications.

          -  Have a history of significant sleep disorder, including sleep apnea or narcolepsy.

          -  Have a history of orthostatic hypotension, vertigo, syncopy, or presyncopy.

          -  Have a history of brain injury, including a history of concussions.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Vince &amp; Associates Clinical Research, Inc.</name>
      <address>
        <city>Overland Park</city>
        <state>Kansas</state>
        <zip>66212</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 15, 2017</study_first_submitted>
  <study_first_submitted_qc>September 15, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">September 18, 2017</study_first_posted>
  <last_update_submitted>December 11, 2017</last_update_submitted>
  <last_update_submitted_qc>December 11, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 13, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Substance-Related Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alprazolam</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

